Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria unveils Empax global partnership platform to link international sponsors with its clinical delivery network; Psyence signs for Phase IIb trial.
Latest Stories
Global Momentum Continues as Immuron Delivers Double-Digit Q3 Sales Growth in Australia
Immuron delivers double-digit Q3 Travelan growth, led by Australia +15% to AUD 0.9m; Canada doubles; global Q3 sales AUD 1.5m +16%.
BlinkLab Raises A$17.5m to Fund FDA Autism Diagnostic Clearance and Advance ADHD Trials
BlinkLab raises oversubscribed A$17.5m to push FDA autism Dx1 clearance and start ADHD Dx2 trials; Morocco rollout underpins real-world data.
Genetic Signatures Inks 10-Year Danish Supply Deal for GI Screening Technology
GSS signs 10-year Danish deal with Hvidovre Hospital for EasyScreen Pan-Enteric; boosts recurring revenue, EMEA growth; first-year 28k samples from Sept 2026.
Orthocell Secures Access to 221 US Military & VA Medical Centres for Remplir
Orthocell wins access to 221 US DoD/VA centres for Remplir, a major US market expansion as HY26 revenue hits A$6.2m and cash sits at A$49.4m.
Immutep Granted FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down.
AVITA Medical Reports Accelerating Grafting Times in Positive Interim Results for Cohealyx-I Study
AVITA Medical reports Cohealyx-I interim: mean grafting 13.6 days vs 33.2 benchmark; early grafting, strong clinician adoption signals.
PainChek Inks Landmark 20,000-Bed North America Deployment with Sabra Health Care REIT
PainChek inks landmark 20,000-bed North American deployment with Sabra Health Care REIT across 329 facilities, funding beds at $55-75/bed/yr.
Entropy Neurodynamics' TRP-8803 Trial Shows Repeatable Psychedelic Effects in BED Study
Entropy Neurodynamics reports repeatable psychedelic effects in TRP-8803 BED trial; Cohort 2 enrollment advancing; R&D incentives boost cash runway.
Pacific Edge Test Volumes Rise 2.7% in Q4 on Payer Expansion
Pacific Edge (PEB) Q4 test volumes rise 2.7% on payer expansion; eyes Medicare LCD draft by Sept 2026 as coverage broadens, signaling regulatory momentum.
Imricor Medical Systems Advances US Strategy with Pediatric Label Expansion Submission
Imricor submits pediatric NorthStar label via 510(k) to FDA, targeting 250 US children's hospitals; clearance expected this quarter to drive US growth.
Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs
Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.